Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 11;9(1):59-61.
doi: 10.1080/20009666.2019.1565884. eCollection 2019.

Immune thrombocytopenic purpura

Affiliations

Immune thrombocytopenic purpura

Abir Zainal et al. J Community Hosp Intern Med Perspect. .

Abstract

Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by isolated thrombocytopenia (platelet count <150,000 u/L), which is not associated with a systemic illness. ITP is reported in approximately 2 per 100,000 adults. The mean age of diagnosis is 50 years. ITP is more common in females of childbearing age and in pregnancy. In adults, the course is more chronic although spontaneous remission can also occur within months of initial diagnosis. A thorough and timely workup of thrombocytopenia is imperative to rule out other differentials of ITP as it is considered a diagnosis of exclusion. Primary care physicians encounter patients who exhibit signs of thrombocytopenia such as petechiae or purpura on a regular basis. A high index of clinical suspicion is required to accurately diagnose ITP and commence the appropriate treatment including glucocorticoids to increase the chances of a favorable prognosis as described by the authors.

Keywords: Immune thrombocytopenic purpura; corticosteroids; hematology; platelets.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Petechial rash and ecchymosis.
None
An approach to the workup of thrombocytopenia PT- prothrombin, aPTT- activated partial thromboplastin time, DIC- disseminated intravascular coagulation, TTP- thrombotic thrombocytopenic purpura, HUS- hemolytic uremic syndrome, MAHA- microangiopathic hemolytic anemia, MDS- myelodysplastic syndrome, ITP

References

    1. Michel M.Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol. 2009;82(s71):3–7. - PubMed
    1. Provan D, Newland AC.. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875–887. - PMC - PubMed
    1. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol. 2011;153(4):437–450. - PubMed
    1. Nazy I, Moore JC, Clare R, et al. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. Blood. 2016;128(22):2548. - PubMed
    1. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365(8):734–741. - PubMed

LinkOut - more resources